AtriCure UBS Global Healthcare Conference
Review the key takeaways and the transcript of this earnings call.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Alrighty. Oh, goodness me. That was powerful. Welcome. Thanks, everyone. It is Patrick Wood on the UBS MedTech team, and appreciate everyone for joining us. And big thank you to Angie, CFO of AtriCure, for agreeing to do this and spend a bit of time with us today.
Thank you for having us.
I really appreciate it. I mean, maybe we could start a little bit big picture with the evolution of AtriCure. I mean, obviously, people can think about it primarily as a surgical AF business, but you actually span quite a bit more than that today.
Correct. Maybe just to level set people in the room, how much the business has evolved from there to where we are today.
Yeah. The company was founded really focused on treating patients who are undergoing cardiac surgery, treating their AFib. You are going into cardiac surgery, and you already have preexisting AFib diagnosis. That is about a third of the patients globally who go into a cardiac surgery procedure, and they have AFib. And we said, "Look, there is something we can do for those patients with an ablation, with managing their appendage, that will help reduce their AFib burden." Since then, I would say the company has looked at minimally invasive therapies. You would never open a patient's chest just to treat their AFib, to think about standalone AFib therapies. That also was what led us into pain management. You think an AFib company, how do you get into pain management? It was, in most thoracic procedures, that is incredibly painful.
When you are accessing the thoracic cavity by spreading the ribs, incredibly painful procedure. We developed a device to reduce that pain that you feel in a thoracic procedure. And we thought it was going to grow our AFib business. We thought this would be beneficial to our standalone AFib therapy business. I mean, it took off like gangbusters just for broad-based cardiothoracic surgeons who said, "Look, there are a lot of other procedures where patients are feeling that pain, and this shows a benefit there." So, I think what is interesting today, started in AFib, it kind of led us to pain management.
Our cardiac surgery market now is entering kind of a revitalization, I would say, because you are looking at not just doing something for AFib patients, but also those patients going into cardiac surgery who ultimately have a higher likelihood of developing postoperative AFib or clinical AFib long term as a result of having that procedure done.
Yeah. I mean, to your perspective, do you view a lot more sternotomies, thoracotomies, and things like that going on just because we are doing a lot more surgical interventions, driving a lot more AFib? How material is that for you for your growth? Because you guys are also disrupting other parts of the market, and that is a big part of your growth. How much is the base market relative to the idiosyncrasies of AtriCure?
Yeah. I think the base market has fantastic opportunity. I mean, you are talking if our management team were sitting up here 10 years ago, we would have talked about a billion-dollar market opportunity. Where we sit today, we are eyeing $10 billion plus, and I think still have designs on how we can expand and use our core strengths, which are ablation technologies, and also finding unique markets where our tools benefit a patient and starting to really cultivate and develop those markets.
So, you guys are growing mid-teens.
Which is definitely at the upper end of our coverage universe. How much of that is, I know EnCompass and things like that are growing well, but how much of that is that product side and penetration within the market overall?
Yeah. So within our cardiac surgery business, you see strong growth between ablation and our appendage management technology. In the U.S. in this past quarter, EnCompass was a big driver behind our open ablation growing 21%. That's a fantastic number for our franchise, our appendage management franchise, in the mid-teens area. So both of those areas are. And these are still primarily focused in on AFib patients. So we see great potential once you start talking about opening the market up to the other two-thirds of patients who could benefit from the technology. Clearly, the biggest growth driver in our company today, and you've seen that all year long and a bit last year too, is our pain management business.
Would definitely want to touch on that shortly. Obviously, the AFib treated patient pool has been, in the U.S. especially, growing very durably and very quickly.
Yeah. For those who are maybe less familiar, could you touch on why you think that is between better upstream diagnostics of patients relative to lifestyle changes, that whole construct?
Yeah. I think AFib is an aging disease. That's been proven time and again. It's interesting, when you go to one of our training courses, the surgeons presenting would say, "If we all lived past 100 years old, every one of us in this room would develop AFib." It's part of the aging process. I think diagnostics are better, which says patients who are going into surgery have a better chance of being treated. I think what has been a game changer for treatment is the EnCompass Clamp. To treat a patient with AFib, if you use the original AtriCure technology, you're talking about a pretty robust procedure, worked incredibly well, but you were adding on 45, 50 minutes and a pretty technically difficult procedure to do.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.
View the full transcript with ProCall participants
2 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
